[go: up one dir, main page]

Csabai et al., 1998 - Google Patents

Complexation of manidipine with cyclodextrins and their derivatives

Csabai et al., 1998

View PDF
Document ID
18060129964223148702
Author
Csabai K
Vikmon M
Szejtli J
Redenti E
Poli G
Ventura P
Publication year
Publication venue
Journal of inclusion phenomena and molecular recognition in chemistry

External Links

Snippet

Abstract Manidipine (MDP,(±)-2-[-(diphenylmethyl)-1-piperazinyl] ethylmethyl-1, 4-dihydro-2, 6-dimethyl-4 (m-nitrophenyl)-3, 5-pyridinedicarboxylate methyl-ester) is a poorlysoluble (< 1 μg/mL) long acting antihypertensive drug. Salt formingwith citric or tartaric acid results in a …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48961—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the conjugate being in the form of a host-guest, i.e. being an inclusion complex, e.g. clathrate, cavitate, fullerene
    • A61K47/48969—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the conjugate being in the form of a host-guest, i.e. being an inclusion complex, e.g. clathrate, cavitate, fullerene inclusion being performed with a cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48169—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
    • A61K47/4823—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative, e.g. starch, chitosan, chitin, cellulose, pectin, cyclodextrin with the pharmacologically active agent being covalently linked to the external surface of the ring structure, a bacterial polysaccharide or oligosaccharide antigen, a glycosaminoglycan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48169—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
    • A61K47/48176—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule the organic macromolecular compound has been obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol

Similar Documents

Publication Publication Date Title
US5855916A (en) Highly soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin
Devarakonda et al. The effect of PAMAM dendrimer generation size and surface functional group on the aqueous solubility of nifedipine
Yang et al. The solubilization of the poorly water soluble drug nifedipine by water soluble 4-sulphonic calix [n] arenes
Devarakonda et al. Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes
Béni et al. Cyclodextrin/imatinib complexation: binding mode and charge dependent stabilities
Patel et al. Multicomponent cyclodextrin system for improvement of solubility and dissolution rate of poorly water soluble drug
JP3509866B2 (en) Novel cyclodextrin derivative particularly usable for dissolving hydrophobic compounds such as drugs and method for preparing the same
Loftsson et al. The influence of water-soluble polymers and pH on hydroxypropyl-β-cyclodextrin complexation of drugs
Tóth et al. Physicochemical characterization and cyclodextrin complexation of the anticancer drug lapatinib
K.‐K. Mong et al. β‐Alanine‐Based Dendritic β‐Peptides: Dendrimers Possessing Unusually Strong Binding Ability Towards Protic Solvents and Their Self‐Assembly into Nanoscale Aggregates through Hydrogen‐Bond Interactions
WO2001010913A1 (en) Potentiation of inclusion complex formation of cyclodextrin derivatives
Csabai et al. Complexation of manidipine with cyclodextrins and their derivatives
Rozou et al. The effect of pH dependent molecular conformation and dimerization phenomena of piroxicam on the drug: cyclodextrin complex stoichiometry and its chromatographic behaviour: A new specific HPLC method for piroxicam: cyclodextrin formulations
Pocrnić et al. Inclusion complexes of loratadine with β-cyclodextrin and its derivatives in solution. Integrated spectroscopic, thermodynamic and computational studies
Barillaro et al. Effect of acidic ternary compounds on the formation of miconazole/cyclodextrin inclusion complexes by means of supercritical carbon dioxide
EP0566142A1 (en) Inclusion complexes of optically active and racemic 1,4-dihydro pyridines with cyclodextrin derivates
Miyake et al. Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin a with dimethyl‐α‐and‐β‐cyclodextrins in aqueous solution
Dollo et al. Inclusion complexation of amide-typed local anaesthetics with β-cyclodextrin and its derivatives. ii. evaluation of affinity constants and in vitro transfer rate constants
Ceborska et al. Structural diversity in the host–guest complexes of the antifolate pemetrexed with native cyclodextrins: gas phase, solution and solid state studies
Gascon et al. Synthesis and Study of Multifunctional Cyclodextrin–Deferasirox Hybrids
Arora et al. Physicochemical characterization and evaluation of telmisartan: hydroxypropyl-βcyclodextrin: Tween 80 inclusion complex
Redenti et al. The terfenadine/β-cyclodextrin inclusion complex
Taneri et al. Influence of cyclodextrin complexation on the physicochemical and biopharmaceutical properties of ketoconazole
Pose-Vilarnovo et al. Sulphamethizole-cyclodextrin-hydroxy propylmethyl cellulose multicomponent complexes
Viernstein et al. Solubility enhancement of low soluble biologically active compounds by β-cyclodextrin and dimethyl-β-cyclodextrin